Amarantus Bioscience Holdings Inc (AMBS)

[zoomboom]

AMBS retained a Swiss neuroscience-focused consulting firm to conduct a full audit of the data derived from these experiments and assist the Company in planning for its IND package.

Well after recent developments this Consulting Firm most likely is helping them with their ORPHAN IND PACKAGE for Retinitis Pigmentosa


http://www.prnewswire.com/news-releases/amarantus-bioscience-reports-statistical-significance-achieved-for-manf-striatal-reinnervation-in-neurorestoration-animal-model-of-parkinsons-disease-189649741.html

The potential for use in something like RP opens a door for Amarantus because Orphan Drug Designation is highly attractive to larger pharmaceutical companies given the potential for strong pricing and guaranteed market exclusivity. We expect the company to provide an update on a potential investigational new drug (IND) filing for MANF in the next few months.

http://seekingalpha.com/article/1629912-amarantus-eyes-orphan-indication-for-manf